Posted inNews and Updates
IDEAYA Biosciences Unveils Latest Clinical Trial Data
IDEAYA Biosciences is set to present new clinical trial data on its targeted oncology pipeline. Discover the latest updates on their precision therapies.
Posted inNews and Updates
Pharma Innovation Update: ADC Trial Wins and EGFR Deals
Explore the latest in pharma: GSK and Merck see ADC trial success, AstraZeneca strikes a $1.5B EGFR deal, and biotechs refine complex patent strategies.
Posted inNews and Updates
XmAb819 Shows Promise in Advanced Kidney Cancer Trial
Explore the latest data on XmAb819 for advanced renal cell carcinoma. Discover how this bispecific antibody targets tumor cells in a new Phase 1 study.
Posted inNews and Updates
IDEAYA Reveals New Data for Darovasertib and IDE849 at ESMO
Explore the latest clinical updates on darovasertib and IDE849 as IDEAYA Biosciences prepares to present breakthrough oncology data at ESMO 2026.
Posted inNews and Updates
GSK Halts Cough Drug Development After Phase 3 Trial Failure
GSK has discontinued its Phase 3 trial for a chronic cough drug candidate after it failed to meet key efficacy endpoints. Learn the details behind the cut.
Posted inNews and Updates
EU Packaging Rules: Are Medical Devices Really Exempt?
Are medical devices exempt from the EU’s new packaging laws? Learn how the PPWR impacts sterile barrier systems and what manufacturers must do to comply.
Posted inNews and Updates
New Alzheimer’s Drug Reverses DNA Damage and Brain Swelling
A novel Alzheimer’s treatment shows promise in repairing damaged DNA and reducing brain inflammation. Learn how this breakthrough may protect neurons.
Posted inNews and Updates
Trellis Bioscience Secures $9M to Advance TRL1068 Therapy
Trellis Bioscience raises $9M for TRL1068, a promising monoclonal antibody designed to combat antibiotic-resistant bacterial infections.
Posted inNews and Updates
Huahai Recruits Hengrui Quality Chief Amid FDA Hurdles
Zhejiang Huahai recruits a new quality lead from Hengrui to address recent FDA manufacturing citations and improve regulatory compliance standards.
Posted inNews and Updates
New Betting Markets Open for FDA Drug Approval Outcomes
Explore how Kalshi’s new prediction markets are enabling bets on FDA drug approvals and clinical trial results, blending financial risk with medical data.